GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALGEN • FR0004053510

2.45 EUR
+0.03 (+1.24%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALGEN. ALGEN was compared to 84 industry peers in the Biotechnology industry. ALGEN has an average financial health and profitability rating. ALGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • ALGEN had positive earnings in the past year.
  • In the past year ALGEN has reported a negative cash flow from operations.
  • In multiple years ALGEN reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALGEN has a Return On Assets of 3.31%. This is amongst the best in the industry. ALGEN outperforms 80.95% of its industry peers.
  • The Return On Equity of ALGEN (7.00%) is better than 79.76% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 3.17%, ALGEN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 11.98%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • ALGEN has a better Profit Margin (6.14%) than 79.76% of its industry peers.
  • ALGEN's Operating Margin of 5.97% is fine compared to the rest of the industry. ALGEN outperforms 75.00% of its industry peers.
  • The Gross Margin of ALGEN (94.91%) is better than 92.86% of its industry peers.
  • In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
  • The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
  • ALGEN has a better debt/assets ratio than last year.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ALGEN has an Altman-Z score of 1.74. This is a bad value and indicates that ALGEN is not financially healthy and even has some risk of bankruptcy.
  • ALGEN has a Altman-Z score of 1.74. This is in the better half of the industry: ALGEN outperforms 69.05% of its industry peers.
  • A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.71, ALGEN perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.74
ROIC/WACC0.43
WACC7.3%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • ALGEN has a Current ratio of 2.41. This is comparable to the rest of the industry: ALGEN outperforms 52.38% of its industry peers.
  • ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • ALGEN has a Quick ratio (2.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.46% over the past year.
  • Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
  • The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
  • ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.33 indicates a correct valuation of ALGEN.
  • 91.67% of the companies in the same industry are more expensive than ALGEN, based on the Price/Earnings ratio.
  • ALGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.67.
Industry RankSector Rank
PE 16.33
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 90.48% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.32
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENOWAY SA

EPA:ALGEN (2/5/2026, 7:00:00 PM)

2.45

+0.03 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap23.23M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (145.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 16.33
Fwd PE N/A
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.87
EV/EBITDA 8.32
EPS(TTM)0.15
EY6.12%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.74
F-Score3
WACC7.3%
ROIC/WACC0.43
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


What is the profitability of ALGEN stock?

GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ALGEN stock?

The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16.33 and the Price/Book (PB) ratio is 1.26.


What is the financial health of GENOWAY SA (ALGEN.PA) stock?

The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.